Nanoparticle treatment for severe inflammation and sepsis
Multimodal Nanoparticles for Severe Inflammation and Sepsis
A new nanoparticle treatment aims to calm dangerous immune overreactions in people with sepsis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11333234 on NIH RePORTER |
What this research studies
Researchers are developing biodegradable polymer nanoparticles that can tune the innate immune response and reduce harmful inflammation. In lab and mouse models of sepsis these "immunomodulatory nanoparticles" improved survival. The team will refine the particles and delivery approaches so they could work across different sepsis types and immune states. The long-term aim is to translate these findings into treatments that can be tested in people with severe infections.
Who could benefit from this research
Good fit: Ideal candidates would be adults hospitalized with sepsis or severe systemic inflammation who meet the safety and enrollment criteria for early clinical testing.
Not a fit: People with conditions not driven by infection-related inflammation, patients outside the trial's age or safety eligibility, or those with immune-suppressed sepsis endotypes may not receive benefit.
Why it matters
Potential benefit: If successful, this approach could reduce deaths and long-term health problems after sepsis by rebalancing the immune system.
How similar studies have performed: Related nanoparticle immunotherapies have shown benefit in animal models but similar approaches are largely untested in human patients.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Pearson, Ryan Matthew — University of Maryland Baltimore
- Study coordinator: Pearson, Ryan Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.